Trust in the FDA is collapsing. It’s time to get really transparent about our food and our drugs

FDA trust is falling sharply, with only about half of Americans saying they trust the agency (down from roughly three-quarters two years ago), driven by perceived political interference. The article cites examples where FDA scientists recommended tighter oversight of peptide therapies while HHS Secretary Robert F. Kennedy Jr. pushed to loosen it, raising concerns about regulatory consistency for biotech sponsors. It also highlights potential read-through risk to investors and the wider innovation ecosystem from real or perceived “about-faces” in review standards (e.g., Moderna’s mRNA influenza vaccine application), even as Acting Commissioner Kyle Diamantas begins revisiting high-profile decisions.

Analysis

The market mechanism here is not immediate approval risk; it is the discount rate applied to future biotech cash flows. When sponsors believe FDA standards can move after trial design is locked, the cost of capital rises first for single-asset, pre-revenue names and only later for the broader sector. That makes XBI more vulnerable than IBB, and makes names like BHVN, REPL, QURE, and RGNX structurally dependent on clean regulatory process rather than just data quality.

Near term, the biggest risk is financing and sentiment, not scientific read-through. Over the next 1-3 months, any additional FDA reversal or mixed messaging should widen bid-ask spreads, push smaller programs toward more dilutive raises, and increase the value of partners with diversified pipelines. Over 6-18 months, if the agency re-establishes predictable review standards, the same names could rerate sharply because the market currently prices a persistent process premium, not just product-specific risk.

The contrarian view is that this may be more of a trust narrative than a lasting earnings shock. If the acting leadership gives explicit guidance on evidentiary standards or resolves a few high-profile cases cleanly, the relief rally in battered biotech could be fast and violent. The key falsifier is a concrete procedural reset from the FDA before the next financing window or decision cycle; that would argue for covering shorts and rotating back into high-beta biotech.

Key Decisions for Investors

• Short XBI / long IBB for 1-3 months as a relative-value hedge against rising regulatory-process risk; target 5-8% relative downside in XBI with a stop if FDA guidance becomes clearer or XBI outperforms by ~5%.
• Use rallies to build a small short basket in BHVN, REPL, QURE, and RGNX via put spreads or outright shorts into any FDA-related strength; thesis is higher cost of capital and lower probability-adjusted multiples, not immediate fundamental deterioration.
• Trade MRNA vs SNY as a tactical pair: short MRNA / long SNY if regulatory unpredictability around mRNA vaccine pathways stays elevated; best risk/reward over the next 4-8 weeks, with the short invalidated by a clear FDA reaffirmation of review standards.
• If the FDA issues a transparent reversal or explicit evidentiary framework, cover pre-revenue biotech shorts quickly and pivot to a long beta basket in XBI; expect a sharp 1-2 day relief move and potentially 10%+ upside in the highest short-interest names.